Cargando…
Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4–C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pai...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Spine Surgery
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917776/ https://www.ncbi.nlm.nih.gov/pubmed/27340537 http://dx.doi.org/10.4184/asj.2016.10.3.553 |
_version_ | 1782438997658697728 |
---|---|
author | Kajiwara, Daisuke Kamoda, Hiroto Yonemoto, Tsukasa Iwata, Shintaro Ishii, Takeshi Tsukanishi, Toshinori Ohtori, Seiji Yamazaki, Masashi Okawa, Akihiko |
author_facet | Kajiwara, Daisuke Kamoda, Hiroto Yonemoto, Tsukasa Iwata, Shintaro Ishii, Takeshi Tsukanishi, Toshinori Ohtori, Seiji Yamazaki, Masashi Okawa, Akihiko |
author_sort | Kajiwara, Daisuke |
collection | PubMed |
description | A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4–C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence. |
format | Online Article Text |
id | pubmed-4917776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Society of Spine Surgery |
record_format | MEDLINE/PubMed |
spelling | pubmed-49177762016-06-23 Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor Kajiwara, Daisuke Kamoda, Hiroto Yonemoto, Tsukasa Iwata, Shintaro Ishii, Takeshi Tsukanishi, Toshinori Ohtori, Seiji Yamazaki, Masashi Okawa, Akihiko Asian Spine J Case Report A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4–C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence. Korean Society of Spine Surgery 2016-06 2016-06-16 /pmc/articles/PMC4917776/ /pubmed/27340537 http://dx.doi.org/10.4184/asj.2016.10.3.553 Text en Copyright © 2016 by Korean Society of Spine Surgery http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Kajiwara, Daisuke Kamoda, Hiroto Yonemoto, Tsukasa Iwata, Shintaro Ishii, Takeshi Tsukanishi, Toshinori Ohtori, Seiji Yamazaki, Masashi Okawa, Akihiko Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor |
title | Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor |
title_full | Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor |
title_fullStr | Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor |
title_full_unstemmed | Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor |
title_short | Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor |
title_sort | denosumab for treatment of a recurrent cervical giant-cell tumor |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917776/ https://www.ncbi.nlm.nih.gov/pubmed/27340537 http://dx.doi.org/10.4184/asj.2016.10.3.553 |
work_keys_str_mv | AT kajiwaradaisuke denosumabfortreatmentofarecurrentcervicalgiantcelltumor AT kamodahiroto denosumabfortreatmentofarecurrentcervicalgiantcelltumor AT yonemototsukasa denosumabfortreatmentofarecurrentcervicalgiantcelltumor AT iwatashintaro denosumabfortreatmentofarecurrentcervicalgiantcelltumor AT ishiitakeshi denosumabfortreatmentofarecurrentcervicalgiantcelltumor AT tsukanishitoshinori denosumabfortreatmentofarecurrentcervicalgiantcelltumor AT ohtoriseiji denosumabfortreatmentofarecurrentcervicalgiantcelltumor AT yamazakimasashi denosumabfortreatmentofarecurrentcervicalgiantcelltumor AT okawaakihiko denosumabfortreatmentofarecurrentcervicalgiantcelltumor |